RxDoctor Payments DataLook up a doctor →

Leslie Stefanowicz, NP

Family · Dartmouth, MANPI 1639159783

Payments from drug & device makers

$56,165in general payments, 2019–2025

Across 950 payments — averaging $59.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$28K
  • GSK$13K
  • AstraZeneca$5K
  • Sanofi$1K
  • LEO Pharma Inc.$1K
  • Genentech USA, Inc.$1K
  • plus $8K from 34 others

What the payments were for

  • Consulting fees$1,6263%
  • Speaking & faculty fees$28,27750%
  • Travel & lodging$4,9359%
  • Food & beverage$21,16838%
  • Education$1590%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,165 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$129,408
Medicare patients
128
Services billed
3,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab40$151,122
Fasenra PenBenralizumab18$102,245
Dupixent SyringeDupilumab20$73,646
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$57,652
XolairOmalizumab23$56,321
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$42,420
Breo ElliptaFluticasone/Vilanterol33$17,756
Spiriva RespimatTiotropium Bromide23$16,574
Arnuity ElliptaFluticasone Furoate38$8,198
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$5,589
SymbicortBudesonide/Formoterol Fumarate23$5,260
Incruse ElliptaUmeclidinium Bromide15$5,144
Epinephrine29$4,499
DuleraMometasone/Formoterol11$3,979
Fluticasone Propionate HfaFluticasone Propionate11$3,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$12,627$239,872196 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$4,607$50,57485 claims
Boehringer IngelheimSpiriva Respimat$424$16,57423 claims
Hikma Pharmaceuticals USAEpinephrine$17$4,49929 claims
MerckDulera$38$3,97911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.

Other family in Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →